Arcellx, Inc. (ACLX)
After hours:
| Previous close | 51.38 |
| Open | 51.35 |
| Bid | 51.82 x 200 |
| Ask | 51.96 x 100 |
| Day's range | 50.87 - 52.68 |
| 52-week range | 30.74 - 75.10 |
| Volume | |
| Avg. volume | 459,266 |
| Market cap | 2.767B |
| Beta (5Y monthly) | 0.02 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.47 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 80.31 |
Insider MonkeyShould You Be Bullish on Arcellx (ACLX)?
Baron Funds, an investment management company, released its “Baron Health Care Fund” first quarter 2024 investor letter. A copy of the same can be downloaded here. The fund advanced 8.92% (Institutional Shares) in the quarter compared to an 8.52% gain for the Russell 3000 Health Care Index (benchmark) and a 10.56% increase for the S&P […]
Business WireArcellx to Participate in the 23rd Annual Needham Virtual Healthcare Conference
REDWOOD CITY, Calif., April 04, 2024--Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced that management will participate in a fireside chat at the 23rd Annual Needham Virtual Healthcare Conference on Wednesday, April 10, at 12:45 p.m. ET.
ZacksHow Arcellx (ACLX) Stock Stands Out in a Strong Industry
Arcellx (ACLX) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
